Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer.

Hille C, Gorges TM, Riethdorf S, Mazel M, Steuber T, Amsberg GV, König F, Peine S, Alix-Panabières C, Pantel K.

Cells. 2019 Sep 11;8(9). pii: E1067. doi: 10.3390/cells8091067.

2.

Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H.

Knipper S, Beyer B, Mandel P, Tennstedt P, Tilki D, Steuber T, Graefen M.

World J Urol. 2019 Sep 11. doi: 10.1007/s00345-019-02950-0. [Epub ahead of print]

PMID:
31511970
3.

Comparison of intra- and postoperative analgesia and pain perception in robot-assisted vs. open radical prostatectomy.

Knipper S, Hagedorn M, Sadat-Khonsari M, Tian Z, Karakiewicz PI, Tilki D, Heinzer H, Michl U, Steuber T, von Breunig F, Zöllner C, Graefen M.

World J Urol. 2019 Sep 6. doi: 10.1007/s00345-019-02938-w. [Epub ahead of print]

PMID:
31493108
4.

Erratum zu: Therapiesituation beim metastasierten kastrationsnaiven Prostatakarzinom (mCNPC) und die Auswirkungen im klinischen Alltag.

Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.

Urologe A. 2019 Aug;58(8):924. doi: 10.1007/s00120-019-0985-3. German. No abstract available.

PMID:
31236656
5.

The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer.

De Santis M, Steuber T.

ESMO Open. 2019 Apr 12;4(2):e000484. doi: 10.1136/esmoopen-2018-000484. eCollection 2019. No abstract available.

6.

Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial.

Mandel PC, Huland H, Tiebel A, Haese A, Salomon G, Budäus L, Tilki D, Chun F, Heinzer H, Graefen M, Pantel K, Riethdorf S, Steuber T.

Eur Urol Focus. 2019 Jun 6. pii: S2405-4569(19)30145-2. doi: 10.1016/j.euf.2019.05.008. [Epub ahead of print]

PMID:
31178293
7.

[PSA increase after definitive treatment].

Maurer T, Hadaschik B, Budäus L, Steuber T, Salomon G, Horn T, Herrmann K, Weber M, Giesel FL, Berliner C, Eiber M.

Urologe A. 2019 May;58(5):569-582. doi: 10.1007/s00120-019-0931-4. German.

PMID:
31049635
8.

Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy.

Klippenstein P, Schlomm T, von Amsberg G, Beyer B, Pompe RS, Michl U, Salomon G, Thederan I, Budäus L, Heinzer H, Tilki D, Haese A, Huland H, Graefen M, Steuber T, Tennstedt P.

Urol Oncol. 2019 Sep;37(9):575.e1-575.e7. doi: 10.1016/j.urolonc.2019.04.007. Epub 2019 Apr 30.

PMID:
31047783
9.

[Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].

Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.

Urologe A. 2019 Sep;58(9):1066-1072. doi: 10.1007/s00120-019-0925-2. Review. German. Erratum in: Urologe A. 2019 Aug;58(8):924.

PMID:
31041460
10.

Nondihydropyridine Calcium Channel Blockers for the Treatment of Proteinuria: A Review of the Literature.

Steuber TD, Lee J, Holloway A, Andrus MR.

Ann Pharmacother. 2019 Oct;53(10):1050-1059. doi: 10.1177/1060028019843644. Epub 2019 Apr 9.

PMID:
30966785
11.

Direct Oral Anticoagulants in Chronic Liver Disease.

Steuber TD, Howard ML, Nisly SA.

Ann Pharmacother. 2019 Oct;53(10):1042-1049. doi: 10.1177/1060028019841582. Epub 2019 Apr 4.

PMID:
30947523
12.

A comparative study of robot-assisted and open radical prostatectomy in 10 790 men treated by highly trained surgeons for both procedures.

Haese A, Knipper S, Isbarn H, Heinzer H, Tilki D, Salomon G, Michl U, Steuber T, Budäus L, Maurer T, Tennstedt P, Huland H, Graefen M.

BJU Int. 2019 Jun;123(6):1031-1040. doi: 10.1111/bju.14760. Epub 2019 Apr 12.

PMID:
30927303
13.

Implementation of Intraoperative Frozen Section During Radical Prostatectomy: Short-term Results from a German Tertiary-care Center.

Preisser F, Theissen L, Wild P, Bartelt K, Kluth L, Köllermann J, Graefen M, Steuber T, Huland H, Tilki D, Roos F, Becker A, Chun FK, Mandel P.

Eur Urol Focus. 2019 Mar 21. pii: S2405-4569(19)30082-3. doi: 10.1016/j.euf.2019.03.007. [Epub ahead of print]

PMID:
30905598
14.

A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer.

Eichenauer T, Hussein M, Hube-Magg C, Kluth M, Büscheck F, Höflmayer D, Tsourlakis MC, Steurer S, Clauditz TS, Luebke AM, Burandt E, Wilczak W, Hinsch A, Dum D, Beyer B, Steuber T, Huland H, Graefen M, Simon R, Sauter G, Melling N, Schlomm T, Minner S.

Oncotarget. 2019 Mar 1;10(18):1729-1744. doi: 10.18632/oncotarget.26739. eCollection 2019 Mar 1.

15.

Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment.

Beckmann A, Spalteholz J, Langer F, Heinzer H, Budäus L, Tilki D, Michl U, Soave A, Steuber T, Veleva V, Salomon G, Haese A, Huland H, Graefen M, Isbarn H.

World J Urol. 2019 Feb 6. doi: 10.1007/s00345-019-02668-z. [Epub ahead of print]

PMID:
30725166
16.

Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery.

Knipper S, Tilki D, Mansholt J, Berliner C, Bernreuther C, Steuber T, Maurer T, Graefen M.

Eur Urol Focus. 2019 Jan;5(1):50-53. doi: 10.1016/j.euf.2018.09.014. Epub 2018 Oct 3.

PMID:
30292421
17.

Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies.

Steuber T, Tennstedt P, Macagno A, Athanasiou A, Wittig A, Huber R, Golding B, Schiess R, Gillessen S.

BJU Int. 2019 May;123(5):826-833. doi: 10.1111/bju.14540. Epub 2018 Oct 11.

PMID:
30216634
18.

Accuracy of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography for the Detection of Lymph Node Metastases Before Salvage Lymphadenectomy.

Mandel P, Tilki D, Chun FK, Pristupa E, Graefen M, Klutmann S, Budäus L, Steuber T.

Eur Urol Focus. 2018 Jul 23. pii: S2405-4569(18)30191-3. doi: 10.1016/j.euf.2018.07.025. [Epub ahead of print]

PMID:
30049657
19.

Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer.

Preisser F, Mazzone E, Nazzani S, Bandini M, Tian Z, Marchioni M, Steuber T, Saad F, Montorsi F, Shariat SF, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol. 2018 Dec;74(6):693-696. doi: 10.1016/j.eururo.2018.07.006. Epub 2018 Jul 20.

PMID:
30037529
20.

Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.

Leyh-Bannurah SR, Karakiewicz PI, Pompe RS, Preisser F, Zaffuto E, Dell'Oglio P, Briganti A, Nafez O, Fisch M, Steuber T, Graefen M, Budäus L.

World J Urol. 2019 Mar;37(3):469-479. doi: 10.1007/s00345-018-2396-2. Epub 2018 Jul 10.

PMID:
29992380
21.

Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.

Wilczak W, Wittmer C, Clauditz T, Minner S, Steurer S, Büscheck F, Krech T, Lennartz M, Harms L, Leleu D, Ahrens M, Ingwerth S, Günther CT, Koop C, Simon R, Jacobsen F, Tsourlakis MC, Chirico V, Höflmayer D, Vettorazzi E, Haese A, Steuber T, Salomon G, Michl U, Budäus L, Tilki D, Thederan I, Fraune C, Göbel C, Henrich MC, Juhnke M, Möller K, Bawahab AA, Uhlig R, Adam M, Weidemann S, Beyer B, Huland H, Graefen M, Sauter G, Schlomm T.

Eur Urol. 2018 Sep;74(3):376-386. doi: 10.1016/j.eururo.2018.05.034. Epub 2018 Jun 13.

PMID:
29908878
22.

Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection.

Preisser F, Nazzani S, Bandini M, Marchioni M, Tian Z, Montorsi F, Saad F, Briganti A, Steuber T, Budäus L, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Urol Oncol. 2018 Aug;36(8):365.e1-365.e7. doi: 10.1016/j.urolonc.2018.05.019. Epub 2018 Jun 7.

PMID:
29887241
23.

[Metronomic chemotherapy with oral cyclophosphamide : An individual option for the metastatic castration-resistant prostate cancer patient?]

Knipper S, Mandel P, V Amsberg G, Strölin P, Graefen M, Steuber T.

Urologe A. 2019 Apr;58(4):410-417. doi: 10.1007/s00120-018-0679-2. German.

PMID:
29808369
24.

Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systems.

Pompe RS, Beyer B, Haese A, Preisser F, Michl U, Steuber T, Graefen M, Huland H, Karakiewicz PI, Tilki D.

BJU Int. 2018 Nov;122(5):801-807. doi: 10.1111/bju.14369. Epub 2018 Jun 4.

PMID:
29727912
25.

Glycemic Management in the Bariatric Surgery Population: A Review of the Literature.

Howard ML, Steuber TD, Nisly SA.

Pharmacotherapy. 2018 Jun;38(6):663-673. doi: 10.1002/phar.2120. Review.

PMID:
29722910
26.

Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.

Pompe RS, Gild P, Karakiewicz PI, Bock LP, Schlomm T, Steuber T, Graefen M, Huland H, Tian Z, Tilki D.

Prostate. 2018 Jun;78(9):676-681. doi: 10.1002/pros.23511. Epub 2018 Mar 23.

PMID:
29570821
27.

Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.

Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, Zilli T, Jereczek-Fossa BA, Wetterauer U, Grosu AL, Schultze-Seemann W, Heinzer H, Graefen M, Morlacco A, Karnes RJ, Ost P.

Eur Urol Focus. 2018 Mar 10. pii: S2405-4569(18)30077-4. doi: 10.1016/j.euf.2018.02.015. [Epub ahead of print]

PMID:
29530632
28.

Assessment of Learner Metacognition in a Professional Pharmacy Elective Course.

Steuber TD, Janzen KM, Walton AM, Nisly SA.

Am J Pharm Educ. 2017 Dec;81(10):6034. doi: 10.5688/ajpe6034.

29.

AB0/Rhesus Blood Group Does Not Influence Clinicopathological Tumor Characteristics or Oncological Outcome in Patients Undergoing Radical Prostatectomy.

Oh SJ, Mandel P, Chun FKH, Tennstedt P, Peine S, Hohenhorst JL, Hiller J, Graefen M, Tilki D, Steuber T.

Front Surg. 2017 Dec 18;4:75. doi: 10.3389/fsurg.2017.00075. eCollection 2017.

30.

The Impact of Lymph Node Metastases Burden at Radical Prostatectomy.

Preisser F, Marchioni M, Nazzani S, Bandini M, Tian Z, Pompe RS, Montorsi F, Saad F, Abdollah F, Steuber T, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Focus. 2019 May;5(3):399-406. doi: 10.1016/j.euf.2017.12.009. Epub 2018 Jan 3.

PMID:
29306731
31.

The role of direct oral anticoagulants in the management of venous thromboembolism.

Steuber T.

Am J Manag Care. 2017 Dec;23(20 Suppl):S383-S390. Review.

32.

Pharmacy resident-led student mentoring program: A focus on developing mentoring skills.

Howard ML, Steuber TD, Nisly SA, Wilhoite J, Saum L.

Curr Pharm Teach Learn. 2017 Nov;9(6):1123-1128. doi: 10.1016/j.cptl.2017.07.005. Epub 2017 Aug 18.

PMID:
29233381
33.

Pharmacy residents as primary educators within a professional pharmacy elective.

Howard ML, Steuber TD, Walton AM, Nisly SA.

Curr Pharm Teach Learn. 2017 Sep;9(5):862-868. doi: 10.1016/j.cptl.2017.05.017. Epub 2017 Jun 9.

PMID:
29233316
34.

Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.

Mandel P, Rosenbaum C, Pompe RS, Steuber T, Salomon G, Chun FK, Graefen M, Huland H, Tilki D.

World J Urol. 2017 Dec;35(12):1833-1839. doi: 10.1007/s00345-017-2079-4. Epub 2017 Aug 21.

PMID:
28828530
35.

Radical prostatectomy in oligometastatic prostate cancer.

Mandel P, Steuber T, Graefen M.

Curr Opin Urol. 2017 Nov;27(6):572-579. doi: 10.1097/MOU.0000000000000445. Review.

PMID:
28825924
36.

Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.

Endt K, Goepfert J, Omlin A, Athanasiou A, Tennstedt P, Guenther A, Rainisio M, Engeler DS, Steuber T, Gillessen S, Joos T, Schiess R.

PLoS One. 2017 Aug 2;12(8):e0181557. doi: 10.1371/journal.pone.0181557. eCollection 2017.

37.

Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study.

Steuber T, Berg KD, Røder MA, Brasso K, Iversen P, Huland H, Tiebel A, Schlomm T, Haese A, Salomon G, Budäus L, Tilki D, Heinzer H, Graefen M, Mandel P.

Eur Urol Focus. 2017 Dec;3(6):646-649. doi: 10.1016/j.euf.2017.06.016. Epub 2017 Jul 8.

PMID:
28753877
38.

Incidence, Risk Factors, Management, and Complications of Rectal Injuries During Radical Prostatectomy.

Mandel P, Linnemannstöns A, Chun F, Schlomm T, Pompe R, Budäus L, Rosenbaum C, Ludwig T, Dahlem R, Fisch M, Graefen M, Huland H, Tilki D, Steuber T.

Eur Urol Focus. 2018 Jul;4(4):554-557. doi: 10.1016/j.euf.2017.01.008. Epub 2017 Feb 7.

PMID:
28753847
39.

Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer.

Jacobsen F, Taskin B, Melling N, Sauer C, Wittmer C, Hube-Magg C, Kluth M, Simon R, Pehrke D, Beyer B, Steuber T, Thederan I, Sauter G, Schlomm T, Wilczak W, Möller K, Weidemann SA, Burdak-Rothkamm S.

BMC Cancer. 2017 Jul 26;17(1):504. doi: 10.1186/s12885-017-3489-9.

40.

Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice.

Reza M, Ohlsson M, Kaboteh R, Anand A, Franck-Lissbrant I, Damber JE, Widmark A, Thellenberg-Karlsson C, Budäus L, Steuber T, Eichenauer T, Wollmer P, Edenbrandt L, Trägårdh E, Bjartell A.

Eur Urol Focus. 2016 Dec;2(5):540-546. doi: 10.1016/j.euf.2016.02.013. Epub 2016 Mar 9.

PMID:
28723520
41.

A Multicenter Analysis of Factors Associated With Apixaban-Related Bleeding in Hospitalized Patients With End-Stage Renal Disease on Hemodialysis.

Steuber TD, Shiltz DL, Cairns AC, Ding Q, Binger KJ, Courtney JR.

Ann Pharmacother. 2017 Nov;51(11):954-960. doi: 10.1177/1060028017717282. Epub 2017 Jun 23.

PMID:
28643524
42.

Local Therapy Improves Survival in Metastatic Prostate Cancer.

Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Steuber T, Huland H, Graefen M, Karakiewicz PI.

Eur Urol. 2017 Jul;72(1):118-124. doi: 10.1016/j.eururo.2017.03.020. Epub 2017 Apr 3.

PMID:
28385454
43.

Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.

Burdelski C, Fitzner M, Hube-Magg C, Kluth M, Heumann A, Simon R, Krech T, Clauditz T, Büscheck F, Steurer S, Wittmer C, Hinsch A, Luebke AM, Jacobsen F, Minner S, Tsourlakis MC, Beyer B, Steuber T, Thederan I, Sauter G, Izbicki J, Schlomm T, Wilczak W.

Neoplasia. 2017 Apr;19(4):279-287. doi: 10.1016/j.neo.2017.01.005. Epub 2017 Mar 8.

44.

Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline.

Pompe RS, Karakiewicz PI, Tian Z, Mandel P, Steuber T, Schlomm T, Salomon G, Graefen M, Huland H, Tilki D.

J Urol. 2017 Aug;198(2):354-361. doi: 10.1016/j.juro.2017.02.070. Epub 2017 Feb 16.

PMID:
28216329
45.

Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.

Sauter G, Clauditz T, Steurer S, Wittmer C, Büscheck F, Krech T, Lutz F, Lennartz M, Harms L, Lawrenz L, Möller-Koop C, Simon R, Jacobsen F, Wilczak W, Minner S, Tsourlakis MC, Chirico V, Weidemann S, Haese A, Steuber T, Salomon G, Matiu M, Vettorazzi E, Michl U, Budäus L, Tilki D, Thederan I, Pehrke D, Beyer B, Fraune C, Göbel C, Heinrich M, Juhnke M, Möller K, Bawahab AAA, Uhlig R, Huland H, Heinzer H, Graefen M, Schlomm T.

Eur Urol. 2018 May;73(5):674-683. doi: 10.1016/j.eururo.2017.01.015. Epub 2017 Jan 20.

PMID:
28117112
46.

Ten-year experience of robot-assisted radical prostatectomy: the road from cherry-picking to standard procedure.

Schiffmann J, Haese A, Boehm K, Salomon G, Steuber T, Heinzer H, Huland H, Graefen M, Karakiewicz PI.

Minerva Urol Nefrol. 2017 Feb;69(1):69-75. doi: 10.23736/S0393-2249.16.02563-7. Epub 2016 Mar 9.

PMID:
28009147
48.

Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy.

Adam M, Tennstedt P, Lanwehr D, Tilki D, Steuber T, Beyer B, Thederan I, Heinzer H, Haese A, Salomon G, Budäus L, Michl U, Pehrke D, Stattin P, Bernard J, Klaus B, Pompe RS, Petersen C, Huland H, Graefen M, Schwarz R, Huber W, Loeb S, Schlomm T.

Eur Urol. 2017 Mar;71(3):330-336. doi: 10.1016/j.eururo.2016.11.015. Epub 2016 Nov 22.

PMID:
27887941
49.

p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.

Burdelski C, Dieckmann T, Heumann A, Hube-Magg C, Kluth M, Beyer B, Steuber T, Pompe R, Graefen M, Simon R, Minner S, Tsourlakis MC, Koop C, Izbicki J, Sauter G, Krech T, Schlomm T, Wilczak W, Lebok P.

Tumour Biol. 2016 Sep;37(9):12655-12663. Epub 2016 Jul 21.

PMID:
27444279
50.

Alumni survey as a quality-improvement tool for defining residency success.

Nisly SA, Janzen KM, Steuber TD, Trujillo TN.

Am J Health Syst Pharm. 2016 Nov 1;73(21):1722-1725. No abstract available.

PMID:
27769967

Supplemental Content

Loading ...
Support Center